Oak Ridge Investments LLC Sells 21,574 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Key Points

• Oak Ridge Investments LLC has reduced its stake in Hims & Hers Health, Inc. by 25% after selling over 21,000 shares, now holding a total of 64,768 shares worth approximately $1.91 million.
• Insider trading activity includes CEO Andrew Dudum selling 660,000 shares at an average price of $50.58, reducing his ownership by nearly 23%.
• Hims & Hers reported earnings of $0.17 per share, missing estimates, but posted a significant 72.6% year-over-year revenue increase to $544.83 million.

Oak Ridge Investments LLC lessened its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 25.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,768 shares of the company's stock after selling 21,574 shares during the quarter. Oak Ridge Investments LLC's holdings in Hims & Hers Health were worth $1,914,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in HIMS. UMB Bank n.a. raised its position in Hims & Hers Health by 247.5% in the first quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after acquiring an additional 933 shares in the last quarter. Larson Financial Group LLC grew its stake in Hims & Hers Health by 47.7% during the 1st quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock valued at $42,000 after acquiring an additional 458 shares in the last quarter. Tsfg LLC bought a new stake in shares of Hims & Hers Health in the 1st quarter valued at approximately $46,000. Fifth Third Bancorp grew its stake in shares of Hims & Hers Health by 165.4% in the 1st quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock valued at $46,000 after buying an additional 961 shares in the last quarter. Finally, N.E.W. Advisory Services LLC bought a new stake in shares of Hims & Hers Health in the 1st quarter valued at approximately $49,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 60,000 shares of the stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the completion of the sale, the insider owned 169,940 shares of the company's stock, valued at $9,105,385.20. This represents a 26.09% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Michael Chi sold 17,102 shares of the stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total transaction of $1,021,844.50. Following the sale, the insider directly owned 278,654 shares of the company's stock, valued at $16,649,576.50. The trade was a 5.78% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,273,034 shares of company stock worth $66,425,573 in the last quarter. 13.71% of the stock is currently owned by company insiders.

Hims & Hers Health Stock Performance

HIMS stock traded down $1.04 during mid-day trading on Friday, hitting $46.09. The company had a trading volume of 18,100,049 shares, compared to its average volume of 37,544,380. The firm has a market cap of $10.32 billion, a PE ratio of 57.61, a price-to-earnings-growth ratio of 2.91 and a beta of 2.08. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. Hims & Hers Health, Inc. has a 12 month low of $13.47 and a 12 month high of $72.98. The stock's fifty day moving average price is $52.96 and its two-hundred day moving average price is $45.63.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $544.83 million for the quarter, compared to analysts' expectations of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. Hims & Hers Health's revenue was up 72.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.06 EPS. On average, analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Truist Financial upped their target price on Hims & Hers Health from $45.00 to $48.00 and gave the company a "hold" rating in a research note on Thursday, July 17th. Wall Street Zen cut Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Monday, July 28th. UBS Group set a $30.00 target price on Hims & Hers Health in a report on Monday, June 23rd. Finally, Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $39.83.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.